WO2002098449A1 - Medications pour lesions des articulations et aliments fonctionnels - Google Patents

Medications pour lesions des articulations et aliments fonctionnels Download PDF

Info

Publication number
WO2002098449A1
WO2002098449A1 PCT/JP2002/005465 JP0205465W WO02098449A1 WO 2002098449 A1 WO2002098449 A1 WO 2002098449A1 JP 0205465 W JP0205465 W JP 0205465W WO 02098449 A1 WO02098449 A1 WO 02098449A1
Authority
WO
WIPO (PCT)
Prior art keywords
cartilage
collagen
joint
collagen peptide
acid
Prior art date
Application number
PCT/JP2002/005465
Other languages
English (en)
Japanese (ja)
Inventor
Takashi Matsumoto
Koutaro Fujita
Yasuki Taguchi
Fumiki Morimatsu
Ryoji Yamada
Saburo Minami
Original Assignee
Nippon Meat Packers, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Meat Packers, Inc. filed Critical Nippon Meat Packers, Inc.
Publication of WO2002098449A1 publication Critical patent/WO2002098449A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/28—Substances of animal origin, e.g. gelatin or collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Definitions

  • the present invention relates to a therapeutic agent for oral joint injury or a functional food. More specifically, it is used for the healing of cartilage and bone damage and defects of joints that are difficult to treat, and for oral joint injury therapeutic agents or functional foods that can repair cartilage and bone of joints more quickly than usual. Related.
  • Cartilage together with bone, plays a role in supporting the body and exists in various forms throughout the body.
  • articular cartilage is present at both ends of the bone, and is called hyaline cartilage because of its characteristics as a matrix.
  • This surface is very smooth, allowing the joints to move due to the smooth sliding between the surfaces.
  • Cartilage also acts in synergy with synovial fluid present in the joint cavity, creating a cushion between bones. Without such an effect, you would not be able to exercise or jump.
  • cartilage part a part consisting of cartilage and synovial fluid (hereinafter referred to as a cartilage part) and a bone part that firmly supports and supports the cartilage part, and can withstand mechanical loads such as weight and shock caused by exercise. it can. Only when the joints perform these functions sufficiently can the animals move. If articular cartilage is defective or damaged, it can be very poor or incomplete if no glucosamine salt is taken. Articular cartilage It has long been said that healing is difficult or takes a very long time to heal. In contrast, it has been reported that the administration of dalcosamine salt restores the cartilage at the defect (Sachiro et al., FOOD Style 21, Vol. 4, No. 6, p. 67-73 (2000)).
  • a joint is a body composed of a cartilage part and a bone part, and dalcosamine salt has no effect on the repair of the bone part, so that it is inferior in the effect of repairing the strength of the joint.
  • Composition for the joint treatment consisting of hydrolyzed collagen protein and Darukosamin to avoid these problems are also known (e.g., W0 9 8/4 4 9 2 9) 0
  • its therapeutic effect is not sufficient
  • better treatment was needed.
  • the cartilage of the joints allows the body to move smoothly by sliding on each other's smooth surfaces and as a cushion between the bones. Therefore, if any damage occurs to the cartilage of the joint, various movement disorders including gait disorders will occur. On the other hand, it is well known that cartilage itself is very hard to heal and takes a very long time to heal or does not heal completely.
  • Joint injury can be caused by injury to the cartilage, or by injury to the cartilage and the bone itself.
  • the defect is healed only when the defect is filled with cartilage.
  • it can only heal a state with low physical strength, in other words, an imperfect state.
  • any impact on the repaired cartilage will destroy it because it is less resistant to mechanical loading than the normal cartilage supported by the bone.
  • the destroyed fragments remain in the joint cavity and cause considerable pain to the patient.
  • not only cartilage but also the bone under the cartilage should be modified promptly to improve the joint's resistance to physical load (physical strength). Need to be restored to normal levels.
  • the present invention seeks to solve these problems.
  • the present inventors have conducted various studies in order to solve this problem, and found that collagen (or collagen peptide), which is a main component of bone formation and is expected to contribute to bone formation, and muco, a component of cartilage.
  • Mucopolysaccharide and Z which are a kind of amino sugar that is a component of polysaccharide and contribute to cartilage repair other than dalcosamine, which is a component of cartilage, and Z or ⁇ ⁇ , which is a component of mucopolysaccharide
  • the inventors have found that the combined administration of an acid can form a normal amount of bone and cartilage, impart normal strength and smoothness, and repair joint damage, thereby completing the present invention. .
  • the synergistic effect of the combined administration of the three components of collagen (or collagen peptide) and dalcosamine salt and mucopolysaccharide (or peruronic acid) makes it possible to achieve a state that is almost completely complete up to now. It allows for the restoration of joints that did not heal or that would take a very long time to heal in less time, allowing for the restoration of normal joint structure.
  • joint administration of collagen or collagen peptide
  • gnorecosamine salt or mucopolysaccharide (or peronic acid)
  • mucopolysaccharide or peronic acid
  • a therapeutic agent for oral joint injury or a functional food comprising at least one selected from collagen and collagen peptide, an amino sugar, and at least one selected from mucopolysaccharides and peronic acid. It is.
  • collagen and Z or collagen peptides, amino sugars, mucopolysaccharides and / or peronic acid are each added at a ratio of 10 to 100: 10 to 100: 5 to 40 (weight). Ratio, the same shall apply hereinafter), or a therapeutic agent for oral joint injury or a functional food.
  • a second object of the present invention is to provide collagen and / or collagen peptide, amino sugar, mucopolysaccharide and / or peronic acid, respectively, in a range of 10 to 100: 10 to 100: 5;
  • the present invention relates to a method for producing a therapeutic agent for oral joint injury or a functional food, which is formulated at a ratio of about 40 to about 40.
  • FIG. 1 is a schematic diagram showing the state of repair of cartilage and bone of a joint, showing the case of a control group.
  • FIG. 2 is a schematic diagram showing the state of repair of the cartilage and bone of the joint, showing the case of glucosamine salt administration alone.
  • FIG. 3 is a schematic diagram showing the repair state of the cartilage and bone of the joint, and shows the case of the collagen peptide alone administration.
  • FIG. 4 is a schematic diagram showing the state of repair of cartilage and bone of a joint, and shows a case where a collagen peptide and a glucosamine salt were administered.
  • FIG. 5 is a schematic diagram showing the state of repair of the cartilage and bone of the joint, showing a case where a collagen peptide, a glucosamine salt and chondroitin sulfate are administered in combination.
  • FIG. 6 is a diagram showing the state of restoration of cartilage and bone of a joint in Test Example 2.
  • the type (type I, type II, type III, etc.) and origin (animal species, site, etc.) are not particularly limited, and various types of collagen can be used.
  • type I collagen derived from skin, bone, tendon, etc. of cattle, pigs, chickens, etc. is used because of its abundant raw materials.
  • Type I collagen derived from cartilage of cattle, pigs and chickens is used.
  • the collagen peptide used in the present invention is obtained by hydrolyzing the above collagen.
  • examples of such peptides include those obtained by hydrolyzing collagen using a proteolytic enzyme such as collagenase, and those obtained by heating or hydrolyzing collagen in the presence of an acid or acid.
  • a hydrolysis method is already known, and a method of purifying and fractionating the obtained collagen peptide is also known, and is well known to those skilled in the art.
  • the molecular weight of the collagen peptide is not particularly limited, but those having an average molecular weight of about 100, 000 or less, preferably about 4, 000 or less are used from the viewpoint of absorbability into the living body. Is done.
  • collagen and collagen peptide may be used in combination.
  • amino sugar used in the present invention examples include glucosamine and galactosamine. These amino sugars may be salts, for example, hydrochloride, sulfate and the like. Further, the amino sugar may be chemically modified, for example, an amino sugar that has been N-acylated or esterified.
  • dalcosamine glucosamine hydrochloride, dalcosamine sulfate, N-acetylglucosamine, galactosamine, N-acetyldarcosamine-16-sulfate and the like are exemplified.
  • the mucopolysaccharides used in the present invention include, for example, acidic mucopolysaccharides (for example, hyaluronic acid, hyaluronosulfate, heparin, chondroitin sulfates, lysozyme substrates, etc.) and neutral mucopolysaccharides.
  • acidic mucopolysaccharides for example, hyaluronic acid, hyaluronosulfate, heparin, chondroitin sulfates, lysozyme substrates, etc.
  • neutral mucopolysaccharides for example, hyaluronic acid, hyaluronosulfate, heparin, chondroitin sulfates, lysozyme substrates, etc.
  • neutral mucopolysaccharides for example, hyaluronic acid, hyaluronosulfate, heparin, chondroitin sul
  • peronic acid examples include, for example, glucuronic acid, iduronic acid and the like.
  • Peronic acid may be a salt, and examples of such a salt include a sodium salt, a potassium salt, and a calcium salt.
  • the mucopolysaccharide and peronic acid may be used in combination.
  • the mixing ratio of the collagen and / or collagen peptide, the amino sugar, the mucopolysaccharide and Z or peronic acid is not particularly limited as long as the effect can be exhibited.
  • the amino sugar, the mucopolysaccharide and / or the peronic acid are each in a ratio of 10 to 100: 10 to 100: 5 to 40, and more preferably 10 to 50: 10 ⁇ : 100: blended at a ratio of 5 to 40.
  • the therapeutic agent for oral joint injury of the present invention comprises the collagen and / or collagen peptide described above.
  • Oral administration for the treatment and prevention of joint injuries. Including). '
  • the active ingredient is mixed with a solid or liquid non-toxic pharmaceutically acceptable carrier suitable for oral administration, and administered in the form of a conventional pharmaceutical preparation.
  • a solid or liquid non-toxic pharmaceutically acceptable carrier suitable for oral administration
  • Such preparations include, for example, oral preparations (eg, Tablets, granules, powders, capsules, and other solid preparations, solutions, suspensions, emulsions, and other liquid preparations, lyophilized preparations, etc.), inhalants, suppositories, enteral infusions, and the like. It can be prepared by conventional means described above.
  • non-toxic carrier for pharmaceutical use examples include glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glyceride, polyethylene glycol, hydroxyethyl starch, ethylene glycol, and polyoxyethylene. Sorpitan fatty acid esters, amino acids, sulbumin, water, physiological saline and the like. If necessary, conventional additives such as a stabilizer, a lubricant, a wetting agent, an emulsifier, and a binder can be appropriately added.
  • the dose of the active ingredient is appropriately selected and determined according to the patient's age, body weight, symptom, degree of disease, administration schedule, formulation, and the like. O.lg / day: LO g or so, may be administered in several divided doses per day.
  • the functional food of the present invention comprises the above-mentioned collagen, Z or collagen peptide, an amino sugar, a mucopolysaccharide and / or peronic acid.
  • the functional food is a concept including ordinary foods, beverages, confectioneries, feeds, and the like.
  • the functional food is eaten as it is, or after adding various nutrients, or contained in food or drink, as a functional food (or food material) useful for treatment and prevention of joint injury.
  • a functional food or food material
  • Good and various foods for example, processed meats such as ham and sausage, processed fishery products such as kamaboko and chikuwa, snacks and other confectionery, breads, butter, dairy products such as powdered milk, tofu, It may be used by adding it to soybean products such as fried food, etc., or added to drinks such as water, fruit juice, milk, and soft drinks.
  • animal feed including pet food and the like
  • the amount of intake in the form of the functional food is appropriately selected and determined according to the age, body weight, symptoms, degree of the disease, the form of the food, etc., and is, for example, about 0.1 g to 10 g per day. Since it has the advantage of not adversely affecting the living body even when ingested in large amounts, larger amounts may be ingested.
  • the therapeutic agent for oral joint injury and functional food of the present invention contains at least one selected from collagen and collagen peptide, an amino sugar, and at least one selected from mucopolysaccharide and peronic acid.
  • the synergistic action of the three can heal not only the cartilage of the joint but also the damage suffered by the bone. In this way, not only the cartilage part but also the bone part is repaired (recovered) at an early stage, so that the strength is stronger and it is possible to return to a more complete healing state quickly.
  • FIGS. 1 and 2 The concept of the joint injury treatment of the present invention is shown in FIGS.
  • FIG. 2 schematically shows the healing state of injury when a composition consisting of peptide and collagen peptide + glucosamine salt + chondroitin sulfate is ingested.
  • Figure 1 shows the case of the control group that received water.
  • the tissue did not recover and the defect was often not filled.
  • it is often occupied by fiber tissue that should not exist.
  • Fig. 2 shows the case where dalcosamine salt was administered alone, the defect was filled with cartilage or cartilage and fiber tissue, and the space was occupied by some tissue compared to the control group to which water was administered. Excellent in point. However, since it is buried with cartilage or cartilage and fibrous tissue, sufficient physical strength cannot be obtained and mechanical load is When given, tissue that has been repaired is often detached or missing again, and has not been completely repaired.
  • FIG. 3 shows the case where collagen peptide was administered, and a small amount of bone appeared under the cartilage even at the same time, unlike the repair of cartilage alone when dalcosamine alone was administered. Present. However, its strength is much lower than that of a normal joint.
  • Fig. 4 shows the case where collagen peptide and dalcosamine salt were administered.Although a large amount of bone was formed below the cartilage, the amount was not sufficient, and the strength was higher than that of a normal joint. And still weak.
  • FIG. 5 shows the case where the collagen peptide, dalcosamine salt, and chondroitin sulfate were administered in combination, and a large amount of bone was formed under the cartilage, and the structure was restored to a structure close to the normal part (non-defective part). Is done. As a result, the healed joint exhibits the necessary and sufficient strength.
  • Test example 2
  • the collagen peptide used for the test was prepared as follows, but is not limited thereto.
  • the raw chicken legs (from broiler) were stirred in a 10-fold volume of diluted hydrochloric acid for at least 24 hours to demineralize and acid swell. After sufficient washing with running water, extraction was performed with about twice the amount of warm water and filtration was performed. The filtrate was treated with an ion exchange resin, and further concentrated until the extract content became 10% or more. This concentrated solution was treated with a protease for 1 hour at 50 ° C. and inactivated by heating. The extract was further concentrated to an extract content of 25-30%, and dried with a spray drier to obtain a powdered collagen peptide.
  • Fig. 6 schematically shows the repaired state.
  • a joint healing index closer to 1 indicates that the joint damage has been repaired to a state closer to normal (1 when fully restored).
  • Table 1 shows the results of the measured joint healing coefficients for the groups to which glucosamine salt alone, collagen peptide alone, dalcosamine salt and collagen peptide, and dalcosamine salt and collagen peptide and chondroitin sulfate were administered in combination. No bone was formed in the group administered glucosamine alone.
  • the collagen peptide alone group In the collagen peptide alone group, the amount of bone formed was small, and conversely, the amount of generated cartilage was larger than in the normal and collagen and dalcosamine combination groups. And the joint healing coefficient was 1.72, which was larger than the normal value1. In the collagen and gnorecosamine administration groups, the collagen peptide alone administration group The joint healing index was 1.45, which is closer to 1, but it was not a complete restoration.
  • Example 2 A tablet was obtained by tableting a mixture having the above composition according to a conventional method.
  • Example 5 After mixing with natural juice (concentrated juice reduction) at a ratio of 500 mg of collagen peptide, 500 mg of glucosamine hydrochloride and 25 mg of chondroitin sulfate per 20 Om of the juice, sterilization was carried out according to a standard method. The fruit juice product was obtained by packaging in an aseptic boutique.
  • Example 5 A mixture of 20 g of collagen peptide, 20 mg of glucosamine hydrochloride, and 4 mg of chondroitin sulfate per 15 g of the pasted meat was mixed with the pasta of the sausage and filled into a sausage casing according to a conventional method, and smoked. It was smoked, sterilized, chilled and packaged to obtain vienna sausage.
  • Example 6 Example 6
  • a winna sausage was obtained in the same manner as in Example 5, except that the mixture was mixed at a ratio of 25 Omg of collagen peptide, 15 Omg of dalcosamine hydrochloride and 10 Omg of londroitin sulfate per 15 g of the ground meat.
  • Example 7
  • Example 8 100 g of water was added to 150 g of chicken sternum cartilage (commonly referred to as “lagen cartilage”), flavored vegetables such as onion, carrot, parsley, celery, and ginger, and pepper were added. . After cooling, the mixture was filtered through a strainer and seasoned with salt and pepper to obtain a tris soup. The soup was mixed at a ratio of 30 Omg of collagen peptide, 30 Omg of dalcosamine hydrochloride and 3 Omg of chondroitin sulfate per 20 Om1 of the soup, sterilized according to a conventional method, and subjected to aseptic packaging to obtain a soup product.
  • Example 8 100 g of water was added to 150 g of chicken sternum cartilage (commonly referred to as “lagen cartilage”), flavored vegetables such as onion, carrot, parsley, celery, and ginger, and pepper were added. . After cooling, the mixture was filtered through a strainer and seasoned with salt and pepper to obtain a tris soup
  • Chicken 40 parts per 100 parts by weight of the kneaded raw material mixture
  • ice 20 parts
  • sorbitol 9.1 parts
  • flour 10 parts
  • vegetable protein 5.3 parts
  • bone meal 5 parts
  • salt 1 part
  • collagen 1 part
  • dalcosamine 7.5 parts
  • chondroitin sulfate 0.4 parts
  • seasoning 0.5 part
  • polymerized phosphate 0.2 part
  • the dough is formed into a 1 cm thick plate, cut into a size of 1 Ocm long and 1.5 cm short, and the convection 'oven set at 120 ° C (CM6, Rational)
  • the feed was obtained by baking and cooling.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Rheumatology (AREA)

Abstract

L'invention porte sur des médications orales pour lésions des articulations associées à des aliments fonctionnels, contenant au moins un élément choisi parmi du collagène et des peptides de collagène, et au moins un élément choisi parmi des sucres aminés, des mucopollysaccharides et de l'acide uronique. L'utilisation de ces médications et de ces aliments permet de traiter non seulement les cartilages des articulations, mais également les os qui guérissent rapidement.
PCT/JP2002/005465 2001-06-01 2002-06-03 Medications pour lesions des articulations et aliments fonctionnels WO2002098449A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001166673 2001-06-01
JP2001-166673 2001-06-01

Publications (1)

Publication Number Publication Date
WO2002098449A1 true WO2002098449A1 (fr) 2002-12-12

Family

ID=19009177

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/005465 WO2002098449A1 (fr) 2001-06-01 2002-06-03 Medications pour lesions des articulations et aliments fonctionnels

Country Status (1)

Country Link
WO (1) WO2002098449A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050078A1 (fr) * 2002-12-05 2004-06-17 Takara Bio Inc. Remede
US8227424B2 (en) 2008-09-30 2012-07-24 Nitta Gelatin Inc. Collagen peptide, dipeptide and malady inhibitor
CN103622013A (zh) * 2013-11-21 2014-03-12 青岛贝尔特生物科技有限公司 一种供关节炎患者食用含骨胶原肽的食品配方
CN108785651A (zh) * 2018-07-06 2018-11-13 常同喜 一种增加骨密度的骨胶原肽氨糖片的制备方法
CN112089786A (zh) * 2020-10-19 2020-12-18 琛蓝(美国)营养制品股份有限公司 一种具有多功效的中药复方组合物及其在药物制剂中的应用
US11179424B2 (en) 2015-02-09 2021-11-23 Pharma Foods International Co., Ltd. Hyaluronic acid production promoting agent
CN115500513A (zh) * 2022-10-20 2022-12-23 洛阳清奇古怪生物科技有限公司 一种针对关节保护的组合配方

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022453A1 (fr) * 1993-03-31 1994-10-13 Nutramax Laboratories, Inc. Composition a base de sucres amines et de glycosaminoglycannes pour le traitement et la reparation du tissu conjonctif
WO1998027988A1 (fr) * 1996-12-23 1998-07-02 Nutramax Laboratories, Inc. Composition de sucre amine et de glycosaminoglycane pour le traitement et la reparation du tissu conjonctif
WO1998044929A1 (fr) * 1997-04-10 1998-10-15 Richardson Labs, Inc. Composition renfermant une proteine de collagene hydrolysee et de la glucosamine, pour le traitement des arthroses
WO1999062459A2 (fr) * 1998-06-05 1999-12-09 Nutramax Laboratories, Inc. Utilisation d'agents anabolisants, d'anti-cataboliques, d'antioxydants et d'analgesiques aux fins de la protection, du traitement et de la restauration du tissu conjonctif chez l'homme et l'animal

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022453A1 (fr) * 1993-03-31 1994-10-13 Nutramax Laboratories, Inc. Composition a base de sucres amines et de glycosaminoglycannes pour le traitement et la reparation du tissu conjonctif
WO1998027988A1 (fr) * 1996-12-23 1998-07-02 Nutramax Laboratories, Inc. Composition de sucre amine et de glycosaminoglycane pour le traitement et la reparation du tissu conjonctif
WO1998044929A1 (fr) * 1997-04-10 1998-10-15 Richardson Labs, Inc. Composition renfermant une proteine de collagene hydrolysee et de la glucosamine, pour le traitement des arthroses
WO1999062459A2 (fr) * 1998-06-05 1999-12-09 Nutramax Laboratories, Inc. Utilisation d'agents anabolisants, d'anti-cataboliques, d'antioxydants et d'analgesiques aux fins de la protection, du traitement et de la restauration du tissu conjonctif chez l'homme et l'animal

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050078A1 (fr) * 2002-12-05 2004-06-17 Takara Bio Inc. Remede
US8227424B2 (en) 2008-09-30 2012-07-24 Nitta Gelatin Inc. Collagen peptide, dipeptide and malady inhibitor
US8410062B2 (en) 2008-09-30 2013-04-02 Nitta Gelatin Inc. Collagen peptide, dipeptide and malady inhibitor
CN103622013A (zh) * 2013-11-21 2014-03-12 青岛贝尔特生物科技有限公司 一种供关节炎患者食用含骨胶原肽的食品配方
US11179424B2 (en) 2015-02-09 2021-11-23 Pharma Foods International Co., Ltd. Hyaluronic acid production promoting agent
CN108785651A (zh) * 2018-07-06 2018-11-13 常同喜 一种增加骨密度的骨胶原肽氨糖片的制备方法
CN112089786A (zh) * 2020-10-19 2020-12-18 琛蓝(美国)营养制品股份有限公司 一种具有多功效的中药复方组合物及其在药物制剂中的应用
WO2022082485A1 (fr) * 2020-10-19 2022-04-28 琛蓝(美国)营养制品股份有限公司 Composition de composé de médecine chinoise traditionnelle présentant de multiples effets et son application dans une préparation pharmaceutique
CN115500513A (zh) * 2022-10-20 2022-12-23 洛阳清奇古怪生物科技有限公司 一种针对关节保护的组合配方

Similar Documents

Publication Publication Date Title
US6838440B2 (en) Kolla2-desiccated avian sternal cartilage powder
US7091180B2 (en) Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same
Khora Marine fish-derived bioactive peptides and proteins for human therapeutics
US6476005B1 (en) Oral and injectable nutritional composition
DE102008036954B4 (de) Verwendung einer Aminozucker enthaltenden Zusammensetzung
JP2003048850A (ja) 関節傷害治療剤及び機能性食品
WO2004012665A2 (fr) Composition et methodes de traitement de troubles musculo-squelettiques et de deficiences en collagene et elastine
BR112013022060B1 (pt) produto nutricional, métodos para sua preparação e para melhorar sua coesão, e usos de um polímero de grau alimentício
JP4818177B2 (ja) 高齢者向け骨・筋肉増強促進組成物
EP1765093B1 (fr) Graisses vegetales de substitution pour produits carnes
JP6218732B2 (ja) 変形性関節症予防又は治療用組成物
WO2002098449A1 (fr) Medications pour lesions des articulations et aliments fonctionnels
CN107890117A (zh) 一种浓缩乳清蛋白复合低聚肽营养粉
CN111202231B (zh) 用于制备酱牛肉的营养骨汤、酱牛肉及其制备方法
CA2224709C (fr) Medicament a administration par voie orale, contre la polyarthrite rhumatoide et aliment actif
EP4317450A1 (fr) Extrait de cartilage ayant pour effet d'améliorer la réponse immunitaire, son procédé de préparation et son utilisation
JPWO2006120974A1 (ja) 軟骨代謝異常疾患改善用健康食品及び医薬品組成物
MXPA05004994A (es) Composicion para el tratamiento de enfermedades gastrointestinales.
CN105831738A (zh) 一种多肽氨糖软骨素营养健康食品
KR20050101143A (ko) 글루코사민을 포함하는 퇴행성관절염 예방 및 개선을 위한조성물 및 그 제조방법
JP2004049124A (ja) 大豆７ｓたん白含有タブレット
JP2004166616A (ja) 健康食品
JP2001314173A (ja) 食品用組成物
Kiers Effects of fermented soya bean on digestion, absorption and diarrhoea
Sudha et al. Carbohydrates, Proteins, and Amino Acids: As Natural Products and Nutraceuticals

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase